Slide 1: FY2026 Full Year Results
For personal use only FY2026 FULL YEAR RESULTS A year of transformation, scale & international growth ASX: BLS | August 2026
Slide 2: Disclaimer
DISCLAIMER This presentation (Presentation) has been prepared by BLS Pharmaceuticals Limited ABN 97 084 464 193 (BLS or the Company).The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The information in this presentation is
Slide 3: Investment Proposition
INVESTMENT PROPOSITION PURPOSE PEOPLE PROFIT Delivering profitable growth and positive Manufacturing innovative medicines Creating value for all stakeholders For personal use only cash flow. We continue to invest, scale for global unmet clinical needs from including patients, prescribers, pharmacies
Slide 4: FY26 – A Year of Execution
FY26 – A YEAR OF EXECUTION AMBITIOUS FY26 RECORD GUIDANCE SET PERFORMANCE GERMANY AURORA LATAM UNITED KINGDOM For personal use only FY26 REVENUE STRONG FIRST HALF ADREXPHARMA MANUFACTURING COMMERCIAL ENTRY SCOTLAND FACILITY GUIDANCE PERFORMANCE AGREEMENT COMMENCED INTO COSTA RICA ADVANCING ESTABLISH
Slide 5: FY26 Operational Highlights
FY26 OPERATIONAL HIGHLIGHTS Significant operational progress across Australia and internationally, building the platform for long-term, sustainable growth. For personal use only STRONG AUSTRALIAN STRATEGIC CUSTOMER MAJOR COMMERCIAL MANUFACTURING RELATIONSHIPS BREAKTHROUGH IN PERFORMANCE DEEPENED GER
Slide 6: Scaling Revenue in Growing Markets
SCALING REVENUE IN GROWING MARKETS Revenue increased from $5.2m in FY23 to $74.2m in FY26, with FY26 revenue reaching the top of the Company’s upgraded guidance range. For personal use only REVENUE ($ MILLION) Actual FY27 guidance $120m $100m $105m - $115m 14x REVENUE GROWTH FY23 - FY26 $80m $74.2m
Slide 7: FY27 Guidance
FY27 GUIDANCE Building on a record FY26, BLS is well positioned to deliver continued profitable growth in FY27. For personal use only FY27 REVENUE FY27 ADJ. EBITDA MARGIN 1 $105m – $115m 23% - 26% +42% – +55% vs FY26 FY27 OUTLOOK UNDERPINNED BY MANUFACTURING CONTRACTS & PIPELINE INTERNATIONAL MARKET
Slide 8: Earnings Growth and Operating Leverage
EARNINGS GROWTH AND OPERATING LEVERAGE ADJUSTED EBITDA OPERATING LEVERAGE DRIVERS For personal use only FY25 FY26 $7.0m › $19.0m +171% Higher manufacturing GROWTH volumes and improved utilisation of capacity ADJUSTED EBITDA MARGIN 1 Margin capture through FY25 FY26 sourcing, procurement and 25% › 26
Slide 9: Statutory Profitability
STATUTORY PROFITABILITY FY26 STATUTORY FINANCIAL SUMMARY KEY FINANCIAL OUTCOMES For personal use only FY26 FY251 Revenue $74.2m $28.4m Profit before tax $15.2m $4.9m Net profit after tax2 $15.4m $4.9m $15.2m $15.4m Basic earnings per share 6.9 cents 2.4 cents restated PROFIT BEFORE TAX NET PROFIT AF
Slide 10: Cash Generation Strengthening into FY27
CASH GENERATION STRENGTHENING INTO FY27 Strong revenue growth drove materially higher customer receipts in FY26, alongside significant working capital investment to support increased demand and international supply commitments. CASH RECEIPTS FROM CUSTOMERS1 AND NET CASH FROM OPERATING ACTIVITIES $5.
Slide 11: Inventory Investment Supporting Growth
INVENTORY INVESTMENT SUPPORTING GROWTH BLS re-invested in growing inventory during FY26 to meet growing customer demand and larger domestic and international supply commitments. For personal use only INVENTORY AT 30 JUNE WHY INVENTORY INCREASED 2025 2026 Forecast customer demand $3.6m $17.8m Continu
Slide 12: Working Capital Positioned for Growth
WORKING CAPITAL POSITIONED FOR GROWTH Operating working capital increased materially during FY26, primarily reflecting inventory investment and higher receivables associated with business growth. Inventory increased by $14.2m during FY26 to support higher customer demand and larger supply commitment
Slide 13: FY26 Operational Highlights
FY26 OPERATIONAL HIGHLIGHTS Significant operational progress across Australia and internationally, building the platform for long-term, sustainable growth. For personal use only STRONG AUSTRALIAN STRATEGIC CUSTOMER MAJOR COMMERCIAL MANUFACTURING RELATIONSHIPS BREAKTHROUGH IN PERFORMANCE DEEPENED GER
Slide 14: Australia and International Supply
AUSTRALIA AND INTERNATIONAL SUPPLY Australia is the foundation of the business and our launch pad to building our international infrastructure, commercial relationships and the next stage of our growth. For personal use only AUSTRALIA INTERNATIONAL Established manufacturing base Growing commercial s
Slide 15: Germany: Scaling a Material International Market
GERMANY: SCALING A MATERIAL INTERNATIONAL MARKET H1 FY26 JUNE 2025 SEPTEMBER 2025 (JUL–DEC 2025) MAY 2026 For personal use only Initial German medicinal German import authorisations Initial shipments to Entered into two-year cannabis supply agreement secured ADREXpharma ADREXpharma agreement 1,550kg
Slide 16: Board and Management Team
BOARD AND MANAGEMENT TEAM For personal use only Anthony Ho Samuel Watson Jason Hine Edward Myer Guy Robertson Paul Mitchell Independent Managing Executive Non-Executive Company Secretary CFO Australia Non-executive Chair Director & CEO Director & COO Director & BLS Pharma CFO Experienced ASX Founder
Slide 17: Corporate Structure
CORPORATE STRUCTURE Capital Structure BLS Share Price Performance (12 Months) For personal use only Share price A$0.95 Shares on issue 230.0m $1.20 Options & performance rights 14.5m $1.00 Market capitalisation A$213.9m $0.80 Drawn debt (as at 30 June) A$1.7m $0.60 Cash (as at 30 June) A$13.3m $0.40
Slide 18: Appendix
For personal use only APPENDIX
Slide 19: Consolidated Statement of Profit or Loss
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE YEAR ENDED 30 JUNE 2026 NOTE 2026 2025 RESTATED1 $ $ Continuing operations Revenue from customers 3 74,164,632 28,429,544 Other income 4 68,163 872,962 Other gains/(losses) (254,902) - For personal use only Changes in in
Slide 20: Consolidated Statement of Financial Position
CONSOLIDATED STATEMENT OF FINANCIAL POSITION FOR THE YEAR ENDED 30 JUNE 2026 NOTE 2026 ($) 2025 ($) ASSETS Current Assets Cash and cash equivalents 13,289,017 7,667,522 Trade receivables 7 7,650,239 2,354,934 Current tax receivables 8 230,804 1,171,728 Other current assets 9 2,221,789 938,692 For pe
Slide 21: Consolidated Statement of Cash Flows
CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 30 JUNE 2026 NOTE 2026 ($) 2025 ($) Cash flows from operating activities Receipts of other income (inclusive of goods and services tax) 76,088,011 32,381,281 For personal use only Payments to suppliers and employees (inclusive of goods and serv
Slide 22: Capturing Significant Margin
CAPTURING SIGNIFICANT MARGIN BLS PHARMACEUTICALS For personal use only Raw Active PHARMACEAUTICAL WHOLESALE / Pharmacy / Prescribing Patient Materials Pharmaceutical MANUFACTURING DISTRIBUTION Dispensary Physician (Cultivators of Ingredients Mushrooms, (API) Cannabis) Licenced Licenced (TGA) (ODC, Q
Slide 23: Integrated Pharmaceutical Manufacturing Platform
INTEGRATED PHARMACEUTICAL MANUFACTURING PLATFORM BLS Integrated Pharmaceutical Manufacturing Platform PHARMACEUTICALS For personal use only • Licensed by TGA, QLD Health and ODC • GMP-certified manufacturing capability • Importer/exporter of medicinal cannabis, psilocybin, MDMA PHARMACEAUTICAL WHOLE
Slide 24: Contact
For personal use only CONTACT BLS Pharmaceuticals Limited NWR Communications Sam Watson Melissa Tempra Chief Executive Officer Media & Investor Relations hello@breathelifesciences.com melissa@nwrcommunications.com.au ASX: BLS | August 2026